Diligence memo · auto-generated · as of July 2, 2026
Lucigen Corp
Lucigen Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Lucigen Corp operates in Biotechnology, based in MIDDLETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lucigen Corp has raised $7.0M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.2M on 2014-12-30.
Most recent recorded round closed around 2014-12-30.
Valuation (modeled)modeled
Provath models Lucigen Corp at approximately $99M (range $1.6M–$775M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.48× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era. Within the normal band (148% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 180 months.
Last raise 11.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 49% of Biotechnology peers (4293 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.